Inventaire - your friends and communities are your best library

Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement

Author

Lars Carl Borris

Published in: Journal of Thrombosis and Haemostasis

Date of publication: January 1, 2006

Language: English

Main subject: venous thromboembolism

Bibliographic databases:

Cites articles 12

Date

Title

Authors

March 1, 2001

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement
November 1, 2002

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial
July 1, 2003

Current anticoagulant therapy--unmet clinical needs
September 2004

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
September 2004

Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

, , ,
September 1, 2004

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
January 1, 2004

Current options in the prevention of thromboembolic disease
January 1, 2005

Prevention of venous thromboembolism among hospitalized medical patients
April 1, 2005

New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin
March 2005

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor
October 1, 2005

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
January 1, 2005

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

Article -

Welcome to inventaire

The library of your friends and communities

You are offline